This application is submitted by St. Luke's Hospital in response to RFA number 10, NIH-NCI-DRCCA, Community Clinical Oncology Program. Its authors have joined together a university teaching hospital, a 400 bed general hospital, a 160 bed specialty pediatric hospital, an individual internal medicine-oncology office (one physician) and a radiation therapy outpatient office facility into a consortium under the leadership of a 665 bed private hospital, St. Luke's Hospital, Kansas City, Missouri. Eleven oncologists, three radiation therapists and various other medical disciplines make up the researchers. The purpose of the application to make protocol oriented clinical research procedures available to practicing physicians in community settings thereby enhancing the transfer of current cancer therapy knowledge and treatment to both the patients directly affected and those affected by the physician who comes in contact with the program. It is also designed to develop a segment of the base for diffusion of future knowledge of advancements in chemotherapy, cancer control and prevention research activities. This application involves a large consortium which graduates 160 physicians, a group of pediatric residents, a large group of internal medicine residents, obstetrics and gynecologic residents and general surgery residents. The majority of those residents enter fulltime, non-academic clinical community practice throughout the Midwest.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA035438-03S1
Application #
3557787
Study Section
(SRC)
Project Start
1983-09-15
Project End
1987-08-31
Budget Start
1985-09-01
Budget End
1987-08-31
Support Year
3
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Saint Luke's Hospital
Department
Type
DUNS #
City
Kansas City
State
MO
Country
United States
Zip Code
64111
Karanes, C; Crowley, J; Sawkar, L et al. (1990) Aclacinomycin A in the treatment of multiple myeloma: a Southwest Oncology Group study. Invest New Drugs 8:101-4